Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

Condition:   CLL/SLL Intervention:   Drug: Orelabrutinib Sponsor:   Wang Xin Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials